Evidence map›Paper›PMID 22334658›Full record

ArticleThe Journal of biological chemistry2012

Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

William H Lagarde, Amanda J Blackwelder, John T Minges, Andrew T Hnat, Frank S French, Elizabeth M Wilson

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. The Ser434PheThe application of clinical genetics · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

William H LagardeDepartment of Pediatrics, University of North Carolina, Chapel Hill, North Carolina 27599-7500, USA.
Amanda J Blackwelder
John T Minges
Andrew T Hnat
Frank S French
Elizabeth M Wilson
University of North Carolina at Chapel Hill · USUNC Lineberger Comprehensive Cancer Center

Funding

Tumor stem cells in androgen independent prostate cancerP01CA077739 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FRENCH, FRANK S, MOHLER, JAMES L · 1998 to 2014
$16.8M
TESTIS SPECIFIC HISTONE BINDING PROTEIN (NASP)U54HD035041 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PETRUSZ, PETER · 1997 to 2011
$16.1M
ANDROGEN RECEPTOR REGULATION OF REPRODUCTIVE FUNCTIONR01HD016910 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILSON, ELIZABETH M. · 1985 to 2010
$2.8M
ANDROGEN RECEPTOR REGULATION OF REPRODUCTIVE FUNCTIONR37HD016910 · NICHD · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI WILSON, ELIZABETH M. · 1993 to 2002
$1.1M
NCI NIH HHS P01 CA077739NCI NIH HHS P01-CA77739NICHD NIH HHS HD16910NICHD NIH HHS R01 HD016910NICHD NIH HHS R37 HD016910NICHD NIH HHS U54 HD035041NICHD NIH HHS U54-HD35041
6 · The paper itself

Abstract

Naturally occurring germ line mutations in the X-linked human androgen receptor (AR) gene cause incomplete masculinization of the external genitalia by disrupting AR function in males with androgen insensitivity syndrome. Almost all AR missense mutations that cause androgen insensitivity syndrome are located in the highly structured DNA and ligand binding domains. In this report we investigate the functional defect associated with an AR exon 1 missense mutation, R405S, that caused partial androgen insensitivity. The 46,XX heterozygous maternal carrier had a wild-type Arg-405 CGC allele but transmitted an AGC mutant allele coding for Ser-405. At birth, the 46,XY proband had a bifid scrotum, hypospadias, and micropenis consistent with clinical stage 3 partial androgen insensitivity. Androgen-dependent transcriptional activity of AR-R405S expressed in CV1 cells was less than wild-type AR and refractory in androgen-dependent AR NH(2)- and carboxyl interaction transcription assays that depend on the coregulator effects of melanoma antigen-A11. This mutation created a Ser-405 phosphorylation site evident by the gel migration of an AR-R405S NH(2)-terminal fragment as a double band that converted to the wild-type single band after treatment with λ-phosphatase. Detrimental effects of the R405S mutation were related to the proximity of the AR WXXLF motif (433)WHTLF(437) required for melanoma antigen-A11 and p300 to stimulate transcriptional activity associated with the AR NH(2)- and carboxyl-terminal interaction. We conclude that the coregulator effects of melanoma antigen-A11 on the AR NH(2)- and carboxyl-terminal interaction amplify the androgen-dependent transcriptional response to p300 required for normal human male sex development in utero.

Indexed as

Mutation, MissenseAmino Acid MotifsAndrogen-Insensitivity SyndromeAntigens, NeoplasmBase SequenceBinding SitesE1A-Associated p300 ProteinExonsFemaleHumansMaleNeoplasm ProteinsPhenotypePhosphorylationReceptors, AndrogenTranscriptional ActivationAntigens, NeoplasmE1A-Associated p300 ProteinEP300 protein, humanMAGEA11 protein, humanNeoplasm ProteinsReceptors, Androgen

Identifiers

PMID22334658
PMCPMC3322816
OpenAlexW2091095502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.